ImmuCell Corporation (ICCC) vs Neumora Therapeutics, Inc. Common Stock (NMRA)
A side-by-side comparison of ImmuCell Corporation and Neumora Therapeutics, Inc. Common Stock across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
ICCC
ImmuCell Corporation
$9.97HealthcareDelayed quote: Oct 6, 2026, 2:41 PM EDT
NMRA
Neumora Therapeutics, Inc. Common Stock
$0.48HealthcareDelayed quote: Oct 6, 2026, 2:45 PM EDT
Total return — ICCC vs NMRA
growth of $100 · dividends reinvested · last 3yICCC +101.0% (+26.2%/yr)NMRA -96.8% (-68.1%/yr)ICCC compounded faster over this window
Log scale — wide-divergence pair
ICCC NMRA
ICCC vs NMRA: by the numbers
- •ICCC is the larger company ($90M vs $88M market cap).
- •ICCC is profitable (2.57% net margin) while NMRA runs a net loss (0.00%).
Metrics side by side
Valuation
| Metric | ICCC | NMRA |
|---|---|---|
| P/E ratio | 117.85 | N/A |
| P/S ratio | 2.94 | N/A |
| P/B ratio | 2.87 | 1.99 |
| EV / EBITDA | 15.00 | N/A |
| FCF yield | 4.67% | N/A |
Profitability
| Metric | ICCC | NMRA |
|---|---|---|
| Gross margin | 40.32% | 0.00% |
| Operating margin | 12.60% | 0.00% |
| Net margin | 2.57% | 0.00% |
| ROE | 2.51% | -477.87% |
| ROIC | 8.16% | -216.05% |
Growth (annualized)
| Metric | ICCC | NMRA |
|---|---|---|
| Revenue CAGR (5Y) | 13.74% | N/A |
| Total return CAGR (5Y) | 0.65% | N/A |
Frequently asked
- Is ICCC or NMRA more profitable?
- ICCC runs the higher net margin — ICCC at 2.57% versus NMRA at 0.00%.
Go deeper
Dig into the metrics
ImmuCell P/E ratioImmuCell ROENeumora Therapeutics, Inc. Common Stock ROEImmuCell operating marginNeumora Therapeutics, Inc. Common Stock operating marginImmuCell revenue growthNeumora Therapeutics, Inc. Common Stock revenue growthImmuCell free cash flowNeumora Therapeutics, Inc. Common Stock free cash flow
ImmuCell & Neumora Therapeutics, Inc. Common Stock appear in these rankings
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.